Group 1 - The core viewpoint of the articles highlights the performance of major stock indices, with the Shanghai Composite Index and Shenzhen Component Index both rising by 0.09%, and the ChiNext Index increasing by 0.02% on July 14. The National Index of Free Cash Flow rose over 0.5%, with leading stocks including Shanghai Steel Union, Guodian Nanzi, and Weichai Power [1] - The Ministry of Finance issued a notice on July 11 to guide insurance funds towards long-term stable investments, starting from the 2025 fiscal year. The policy mandates state-owned commercial insurance companies to enhance asset-liability management, optimize asset allocation, and identify quality investment targets with stable cash flow returns [1] - The National Index of Free Cash Flow is designed based on successful overseas products, incorporating domestic market characteristics. It emphasizes quality factors such as liquidity, industry, and ROE stability, with free cash flow rate as the core selection indicator, highlighting the stability of corporate fundamentals and cash flow quality [1] Group 2 - The Free Cash Flow ETF (159201) closely tracks the National Index of Free Cash Flow, selecting stocks with positive and high free cash flow after screening for liquidity, industry, and ROE stability. The index is characterized by high quality and strong risk resistance, making it suitable for long-term investment [2] - The fund management fee is set at an annual rate of 0.15%, and the custody fee at 0.05%, both of which are among the lowest in the market, maximizing benefits for investors [2]

Core Viewpoint - The Hong Kong innovative pharmaceutical sector has gained significant traction in the capital market this year, with a notable performance of related ETFs, indicating strong investor interest and potential growth in the industry [3][5]. Group 1: Performance of ETFs - As of May 30, 2023, the top 17 cross-border ETFs in terms of returns are all related to Hong Kong pharmaceuticals, with annual returns exceeding 40% [3][5]. - Specific ETFs such as the Huatai-PB Hang Seng Innovative Drug ETF and the GF CSI Hong Kong Innovative Drug ETF have reported returns of 43.36% and 42.09% respectively [5]. - The total net inflow of funds into these ETFs has been substantial, with the Huatai-PB ETF seeing an increase of 19.78 million shares [5]. Group 2: Private Equity Interest - Private equity firms have shown a strong preference for newly listed ETFs, particularly in the sci-tech sector, with 104 private equity products appearing in the top ten holdings of 97 newly listed ETFs, holding a total of 1.783 billion shares [3][8]. - The sci-tech ETFs have attracted 32.02% of the total shares held by private equity, indicating a robust interest in high-growth potential sectors [8]. Group 3: Future Outlook for Innovative Pharmaceuticals - Industry experts express optimism regarding the investment potential in innovative pharmaceuticals, citing favorable policies and market conditions as catalysts for growth [4][6]. - The ongoing development of innovative drugs is supported by government initiatives, which aim to streamline approval processes and enhance market access [7][8]. - The increasing demand for innovative drugs is driven by an aging population and heightened health awareness, suggesting a sustainable growth trajectory for the sector [7][8]. Group 4: Free Cash Flow ETFs - Newly listed free cash flow ETFs have emerged as a popular choice among private equity investors, with 16 such ETFs collectively holding 350 million shares [10][12]. - These ETFs focus on companies with strong cash flow, reflecting their true profitability and financial health, which is increasingly appealing in the current market environment [11][12]. - The demand for stable, high-quality investment options has led to a growing interest in free cash flow ETFs, which offer both cash returns and growth potential [12].